深圳市海普瑞药业集团股份有限公司-pg电子游戏

a fully integrated global heparin industrial chain

after years of hard work, hepalink has built a complete heparin industrial supply chain that helps millions of global patients every year and creates steadily growing value for investors.

our products include heparin api and enoxaparin api. enoxaparin is the “gold standard” for anticoagulant and antithrombotic drugs. techdow, a hepalink subsidiary, has become the world’s fourth largest enoxaparin sodium company and owns two enoxaparin sodium brands in the european market, inhixa and neoparin. with the prolongin brand in the chinese market, the company has become the second largest market brand after the reference listed drug. after passing the qec, techdow anticipates rapid new growth. as the world’s largest heparin api company, hepalink has not only been a stable supplier of high-quality heparin api to the world, but has also provided sufficient pharmaceutical ingredients to meet its own demand and achieve rapid growth.

apart from the markets mentioned above, hepalink’s products in the heparin industrial supply chain can also be seen in the markets of dozens of other countries and regions.

the reason why we can successfully integrate the complete heparin industrial supply chain is that we have always upheld our qs (quality safety) philosophy. our integrated supply chain management system ensures the traceability and reliability of the source of raw materials and the stability of supply. our original and leading technologies, advanced technological equipment and strict quality management ensures the high yield and stable quality of products.

thanks to hepalink’s first-rate supply chain management, strict quality management and production standards, world-leading equipment, proprietary production technology, and global marketing network, we are able to lead the global heparin market and ensure our competitive edge in the long run.

after years of molecular biological research on heparin and its derivatives, we have made great progress in developing new drugs around heparin. we have complete proprietary intellectual property rights over heparinoid compound-h1710, which can inhibit the activity of heparinase and will soon enter clinical trials.

the gold standard for anticoagulant and antithrombotic drugs; the clinical application range and advantages of techdow’s enoxaparin sodium injection

cardiology

significantly reduce the mortality/nonfatal mi risk by 17% for stemi patients compared to ufh
the only lmwh proved to be better than ufh in nste-acs
significantly reduce the mortality/mi risk by 23% for pci patients compared to ufh
authoritative guide recommended enoxaparin to manage acs anticoagulant

nephrology

significantly reduce the risk of blood clotting during hemodialysis
authoritative guide recommended lmwh as the anticoagulant drug for hemodialysis patients
used for ns patients to effectively and safely prevent thrombosis

oncology

effectively reduce the vte risk for tumor chemotherapy patients without increasing the risk of hemorrhage
authoritative guide recommended enoxaparin to prevent and treat tumor vte

orthopedics

significantly reduce the risk for tha near-end dvt without increasing the risk of hemorrhage compared to ufh
significantly reduce the risk for tka near-end dvt without increasing the risk of hemorrhage compared to ufh
authoritative guide recommended lmwh as the first-line anticoagulant drug for major operations and vte prevention

obstetrics and gynecology

used for genetic/aps recurrent abortion; high rate of successful and safe childbirth
used for the postpartum anticoagulant therapy of c-section patients
authoritative guide recommended lmwh to prevent and treat obstetrics vte

surgery

effectively reduce the risk of thrombus for patients without increasing the risk of hemorrhage
in 2012, acca guide recommended lmwh as the anticoagulant therapy for patients who had medium and high risk vte operation

internal medicine

effectively reduce the risk of thrombus by 43% for patients without increasing the risk of hemorrhage
in 2015, guide of china medicine recommended lmwh as the anticoagulant therapy for high-risk vte inpatients